{"_buckets": {"deposit": "9b7961ca-7e19-4dbc-a771-a4c8cd00caab"}, "_deposit": {"created_by": 17, "id": "2004293", "owner": "17", "owners": [17], "owners_ext": {"displayname": "repository", "username": "repository"}, "pid": {"revision_id": 0, "type": "depid", "value": "2004293"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:02004293", "sets": ["501"]}, "author_link": [], "item_1615768549627": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_1629683748249": {"attribute_name": "日付", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2023-09-01", "subitem_date_issued_type": "Available"}]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "9", "bibliographicPageEnd": "770", "bibliographicPageStart": "763", "bibliographicVolumeNumber": "27", "bibliographic_titles": [{"bibliographic_title": "Nephrology", "bibliographic_titleLang": "en"}]}]}, "item_9_description_4": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "Aim: Recently, we demonstrated the efficacy of etelcalcetide in the control of secondary hyperparathyroidism (SHPT). This post hoc analysis aimed to evaluate changes in fibroblast growth factor-23 (FGF23) and calciprotein particles (CPPs) after treatment with calcimimetics. Methods: The DUET trial was a 12-week multicenter, open-label, parallel-group, randomized (1:1:1) study with patients treated with etelcalcetide plus active vitamin D (E + D group; n = 41), etelcalcetide plus oral calcium (E + Ca group; n = 41), or control (C group; n = 42) under maintenance haemodialysis. Serum levels of FGF23 and CPPs were measured at baseline, and 6 and 12 weeks after the start. Results: In the linear mixed model, serum levels of FGF23 in etelcalcetide users were significantly lower than those in non-users at week 6 (p \u003c .001) and week 12 (p \u003c .001). When compared the difference between the E + Ca group and the E + D group, serum levels of FGF23 in the E + Ca group were significantly lower than those in the E + D group at week 12 (p = .017). There were no significant differences in the serum levels of CPPs between etelcalcetide users and non-users at week 6 and week 12, while CPPs in the E + Ca group were significantly lower than those in the E + D group (p \u003c .001) at week 12. Conclusion: Etelcalcetide may be useful through suppression of FGF23 levels among haemodialysis patients with SHPT. When correcting hypocalcaemia, loading oral calcium preparations could be more advantageous than active vitamin D for the suppression of both FGF23 and CPPs.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Wiley", "subitem_publisher_language": "en"}]}, "item_9_relation_43": {"attribute_name": "関連情報", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1111/nep.14081", "subitem_relation_type_select": "DOI"}}]}, "item_9_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "\"This is the peer reviewed version of the following article: [Hashimoto, Y, Kato, S, Kuro-o, M, et al. Impact of etelcalcetide on fibroblast growth factor-23 and calciprotein particles in patients with secondary hyperparathyroidism undergoing haemodialysis. Nephrology. 2022; 27( 9): 763- 770. doi:10.1111/nep.14081], which has been published in final form at [https://doi.org/10.1111/nep.14081]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.\"", "subitem_rights_language": "en"}]}, "item_9_source_id_7": {"attribute_name": "収録物識別子", "attribute_value_mlt": [{"subitem_source_identifier": "1320-5358", "subitem_source_identifier_type": "PISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "embargoed access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_f1cf"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Hashimoto, Yusaku", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Kato, Sawako", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Kuro‐o, Makoto", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Miura, Yutaka", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Itano, Yuya", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ando, Masahiko", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Kuwatsuka, Yachiyo", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Maruyama, Shoichi", "creatorNameLang": "en"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2023-09-01"}], "displaytype": "detail", "download_preview_message": "Download / Preview is available from 2023/8/31.", "file_order": 0, "filename": "1_Clean_Accept_DUET_Sub_Nephrology.pdf", "filesize": [{"value": "122 KB"}], "format": "application/pdf", "future_date_message": "Download is available from 2023/8/31.", "is_thumbnail": false, "mimetype": "application/pdf", "size": 122000.0, "url": {"objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/2004293/files/1_Clean_Accept_DUET_Sub_Nephrology.pdf"}, "version_id": "4f961f26-7f9e-4c5c-a490-b5f5bf069829"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Impact of etelcalcetide on fibroblast growth factor‐23 and calciprotein particles in patients with secondary hyperparathyroidism undergoing haemodialysis", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Impact of etelcalcetide on fibroblast growth factor‐23 and calciprotein particles in patients with secondary hyperparathyroidism undergoing haemodialysis", "subitem_title_language": "en"}]}, "item_type_id": "40001", "owner": "17", "path": ["501"], "permalink_uri": "http://hdl.handle.net/2237/0002004293", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2023-01-10"}, "publish_date": "2023-01-10", "publish_status": "0", "recid": "2004293", "relation": {}, "relation_version_is_last": true, "title": ["Impact of etelcalcetide on fibroblast growth factor‐23 and calciprotein particles in patients with secondary hyperparathyroidism undergoing haemodialysis"], "weko_shared_id": -1}